prmarks logo

Aptamer developed by HKBU for treating rare bone disease ‘X-linked hypophosphatemia’ receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA

News provide by
702Padmin
Dec 22, 2024, 21:26 PM PST

Share this article

HONG KONG, Dec. 23, 2024 /PRNewswire/ — A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People’s Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People’s Hospital) has discovered that an aptamer developed by HKBU can…